ArticleFrontiers in oncology2026
Integrative multi-omics analysis implicates the RNF40-LIMA1 axis in hepatocellular carcinoma progression and immune microenvironment remodeling.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ring Finger Protein 40 (RNF40), an E3 ubiquitin ligase, plays context-dependent roles in various cancers, serving as either a tumor suppressor or an oncogene. Critically, RNF40 targets LIM domain and actin-binding protein 1 (LIMA1) for degradation via the ubiquitin-proteasome pathway. LIMA1, which is involved in actin cytoskeleton organization, exerts opposing effects in different cancer types. However, the precise functional relationship between RNF40 and LIMA1 in Hepatocellular Carcinoma (HCC) remains poorly understood. Despite the efficacy of immune checkpoint inhibitors, intrinsic resistance affects 40-60% of patients, necessitating novel epigenetic and ubiquitin-related therapeutic targets. Methods: This study investigated the molecular mechanisms through which RNF40-mediated ubiquitination of LIMA1 influences Hepatocellular Carcinoma (HCC) progression. We utilized an integrative approach combining multi-omics analysis including bulk transcriptomics, single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics with experimental validation using Results: LIMA1 was significantly overexpressed in HCC across multiple transcriptomic and proteomic datasets (log2FC>1.5, Conclusion: Our findings support the biological relevance of a functional RNF40-LIMA1 axis in HCC progression. Together with previously established biochemical evidence of RNF40-mediated LIMA1 ubiquitination and proteasome-dependent degradation, this study provides a rationale for further investigation of the RNF40-LIMA1 axis in HCC. The prognostic and immunotherapy-predictive value of LIMA1 requires validation in independent clinical cohorts and larger ICI-treated HCC datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.